CStone Pharmaceuticals akcijos akcijų analizė | Akcijų kaina | Naujienos | 2616.HK | KYG2588M1006 | A2PEFW | 2025 m. liepa

Data	CStone Pharmaceuticals Akcijų kaina
2025-07-14	0 undefined
2025-07-11	4,89 undefined
2025-07-10	4,84 undefined
2025-07-09	4,61 undefined
2025-07-08	4,72 undefined
2025-07-07	4,73 undefined
2025-07-04	4,74 undefined
2025-07-03	4,19 undefined
2025-07-02	3,84 undefined
2025-06-30	3,88 undefined
2025-06-27	3,87 undefined
2025-06-26	3,99 undefined
2025-06-25	4,07 undefined
2025-06-24	3,94 undefined
2025-06-23	3,87 undefined
2025-06-20	3,72 undefined
2025-06-19	3,63 undefined
2025-06-18	3,90 undefined
2025-06-17	3,80 undefined
2025-06-16	4,22 undefined

Data	CStone Pharmaceuticals Pajamos	CStone Pharmaceuticals EBIT	CStone Pharmaceuticals Pelnas
2027e	801,19 mln. undefined	−48,72 mln. undefined	−52,07 mln. undefined
2026e	590,40 mln. undefined	57,61 mln. undefined	65,09 mln. undefined
2025e	342,56 mln. undefined	−262,58 mln. undefined	−273,36 mln. undefined
2024	407,21 mln. undefined	−81,91 mln. undefined	−91,21 mln. undefined
2023	463,84 mln. undefined	−553,45 mln. undefined	−367,23 mln. undefined
2022	481,36 mln. undefined	−880,02 mln. undefined	−902,68 mln. undefined
2021	243,72 mln. undefined	−1,79 mlrd. undefined	−1,92 mlrd. undefined
2020	1,04 mlrd. undefined	−1,06 mlrd. undefined	−1,22 mlrd. undefined
2019	0 undefined	−1,71 mlrd. undefined	−2,07 mlrd. undefined
2018	0 undefined	−1,02 mlrd. undefined	−469,83 mln. undefined
2017	0 undefined	−242,33 mln. undefined	−107,45 mln. undefined
2016	0 undefined	−262,08 mln. undefined	−117,11 mln. undefined

	Pajamos	EBIT	Pelnas
2016	0 CNY	−262,08 mln. CNY	−117,11 mln. CNY
2017	0 CNY	−242,33 mln. CNY	−107,45 mln. CNY
2018	0 CNY	−1,02 mlrd. CNY	−469,83 mln. CNY
2019	0 CNY	−1,71 mlrd. CNY	−2,07 mlrd. CNY
2020	1,04 mlrd. CNY	−1,06 mlrd. CNY	−1,22 mlrd. CNY
2021	243,72 mln. CNY	−1,79 mlrd. CNY	−1,92 mlrd. CNY
2022	481,36 mln. CNY	−880,02 mln. CNY	−902,68 mln. CNY
2023	463,84 mln. CNY	−553,45 mln. CNY	−367,23 mln. CNY
2024	407,21 mln. CNY	−81,91 mln. CNY	−91,21 mln. CNY
2025e	342,56 mln. CNY	−262,58 mln. CNY	−273,36 mln. CNY
2026e	590,40 mln. CNY	57,61 mln. CNY	65,09 mln. CNY
2027e	801,19 mln. CNY	−48,72 mln. CNY	−52,07 mln. CNY

2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
0	0	0	0	1,04	0,24	0,48	0,46	0,41	0,34	0,59	0,80
-	-	-	-	-	−76,59	97,94	−3,74	−12,10	−15,97	72,51	35,76
-	-	-	-	76,78	55,97	57,80	65,66	58,97	70,18	40,68	29,96
0	0	0	0	797,00	136,00	278,00	304,00	240,00	0	0	0
−117,00	−107,00	−469,00	−2 068,00	−1 221,00	−1 920,00	−902,00	−367,00	−91,00	−273,00	65,00	−52,00
-	−8,55	338,32	340,94	−40,96	57,25	−53,02	−59,31	−75,20	200,00	−123,81	−180,00
0,13	0,16	0,17	0,87	1,05	1,17	1,17	1,26	1,28	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-

2016	2017	2018	2019	2020	2021	2022	2023	2024

0,35	0,14	1,48	2,74	3,39	1,73	1,04	1,03	0,67
0	0	0	0	0	117,60	77,13	172,44	83,93
0	0	0	0	0	0	0	0	0
0	0	0	0	0	61,36	22,19	108,83	286,10
469,82	404,46	125,60	149,03	178,76	52,35	105,51	21,85	46,95
0,82	0,54	1,60	2,89	3,57	1,96	1,25	1,33	1,09
1,03	15,62	14,53	22,23	101,95	187,92	206,57	153,37	130,54
0	0	0	0	0	3,19	3,48	3,54	9,03
0,28	3,18	11,74	40,27	81,99	52,16	21,76	2,26	2,62
0,01	0,22	0,90	1,31	6,51	70,54	159,70	173,05	161,37
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
1,32	19,02	27,17	63,80	190,45	313,81	391,51	332,21	303,56
0,83	0,56	1,63	2,95	3,76	2,27	1,64	1,66	1,39

75,00	75,00	123,00	687,00	787,00	796,00	802,00	860,00	860,00
0,71	0,71	2,69	6,65	8,32	8,46	8,63	8,99	9,00
−236,72	−517,54	−2 078,33	−4 075,79	−5 274,83	−7 162,97	−8 084,40	−8 440,71	−8 546,15
242,66	238,57	−92,68	−94,49	−95,79	−95,41	−95,01	−95,77	−94,79
−33,00	−1 477,00	350,00	0	0	0	0	0	0
0,71	0,43	0,52	2,48	2,95	1,21	0,45	0,46	0,36
0	0,30	4,56	37,30	28,03	33,02	290,41	246,38	338,03
49,89	20,68	86,87	410,01	654,13	814,89	406,69	389,94	197,00
0,01	0,09	1,02	0,01	0,03	0,04	0,20	0,07	0,05
0	0	0	0	0	0	0	0	0
0	0	0	4,34	11,31	43,95	44,92	139,31	93,22
0,06	0,11	1,11	0,46	0,73	0,93	0,95	0,85	0,68
0	0	0	0	72,55	130,25	241,37	224,14	262,76
0	0	0	0	0	0	0	0	0
0	0	7,57	11,10	8,70	1,25	1,25	130,70	84,83
0	0	7,57	11,10	81,24	131,50	242,62	354,83	347,59
0,06	0,11	1,12	0,47	0,81	1,06	1,19	1,21	1,03
0,77	0,54	1,63	2,95	3,76	2,27	1,64	1,66	1,39

2016	2017	2018	2019	2020	2021	2022
−253,00	−342,00	−1 793,00	−2 308,00	−1 221,00	−1 920,00	−902,00
0	0	5,00	11,00	14,00	22,00	44,00
0	0	0	0	0	0	0
39,00	−26,00	27,00	235,00	185,00	64,00	72,00
0	128,00	968,00	980,00	512,00	348,00	173,00
0	0	0	0	1,00	2,00	11,00
0	0	0	0	0	0	0
−213,00	−240,00	−791,00	−1 080,00	−508,00	−1 484,00	−612,00
−1,00	−12,00	−7,00	−10,00	−71,00	−149,00	−101,00
−0,75	0,27	−0,38	−0,66	1,18	−0,83	0,37
−0,75	0,28	−0,37	−0,65	1,25	−0,68	0,47
0	0	0	0	0	0	0
0	0	0	−4,00	51,00	77,00	37,00
0,71	0	1,66	2,20	1,34	0,02	0,00
1,01	0	1,66	2,09	1,39	0,09	0,03
304,00	0	−2,00	−101,00	−1,00	−2,00	−11,00
0	0	0	0	0	0	0
0,06	0,02	0,62	0,43	1,90	−2,28	−0,18
−214,12	−252,70	−799,01	−1 091,15	−579,52	−1 633,16	−714,29
0	0	0	0	0	0	0

CStone Pharmaceuticals Bruto marža	CStone Pharmaceuticals Pelnas-martža	CStone Pharmaceuticals EBIT marža	CStone Pharmaceuticals Pelnas-martža
2027e	58,98 %	−6,08 %	−6,50 %
2026e	58,98 %	9,76 %	11,02 %
2025e	58,98 %	−76,65 %	−79,80 %
2024	58,98 %	−20,12 %	−22,40 %
2023	65,60 %	−119,32 %	−79,17 %
2022	57,83 %	−182,82 %	−187,53 %
2021	56,17 %	−735,86 %	−787,84 %
2020	76,76 %	−102,27 %	−117,54 %
2019	58,98 %	0 %	0 %
2018	58,98 %	0 %	0 %
2017	58,98 %	0 %	0 %
2016	58,98 %	0 %	0 %

	Bruto marža	EBIT marža	Pelnas-martža
2016	58,98 %	0 %	0 %
2017	58,98 %	0 %	0 %
2018	58,98 %	0 %	0 %
2019	58,98 %	0 %	0 %
2020	76,76 %	−102,27 %	−117,54 %
2021	56,17 %	−735,86 %	−787,84 %
2022	57,83 %	−182,82 %	−187,53 %
2023	65,60 %	−119,32 %	−79,17 %
2024	58,98 %	−20,12 %	−22,40 %
2025e	58,98 %	−76,65 %	−79,80 %
2026e	58,98 %	9,76 %	11,02 %
2027e	58,98 %	−6,08 %	−6,50 %

Data	CStone Pharmaceuticals Pardavimai vienai akcijai	CStone Pharmaceuticals EBIT vienai akcijai	CStone Pharmaceuticals Pelnas vienai akcijai
2027e	0,63 undefined	0 undefined	−0,04 undefined
2026e	0,46 undefined	0 undefined	0,05 undefined
2025e	0,27 undefined	0 undefined	−0,21 undefined
2024	0,32 undefined	−0,06 undefined	−0,07 undefined
2023	0,37 undefined	−0,44 undefined	−0,29 undefined
2022	0,41 undefined	−0,75 undefined	−0,77 undefined
2021	0,21 undefined	−1,54 undefined	−1,65 undefined
2020	0,99 undefined	−1,02 undefined	−1,17 undefined
2019	0 undefined	−1,98 undefined	−2,39 undefined
2018	0 undefined	−6,03 undefined	−2,79 undefined
2017	0 undefined	−1,51 undefined	−0,67 undefined
2016	0 undefined	−1,99 undefined	−0,89 undefined

	Pardavimai vienai akcijai	EBIT vienai akcijai	Pelnas vienai akcijai
2016	0 CNY	−1,99 CNY	−0,89 CNY
2017	0 CNY	−1,51 CNY	−0,67 CNY
2018	0 CNY	−6,03 CNY	−2,79 CNY
2019	0 CNY	−1,98 CNY	−2,39 CNY
2020	0,99 CNY	−1,02 CNY	−1,17 CNY
2021	0,21 CNY	−1,54 CNY	−1,65 CNY
2022	0,41 CNY	−0,75 CNY	−0,77 CNY
2023	0,37 CNY	−0,44 CNY	−0,29 CNY
2024	0,32 CNY	−0,06 CNY	−0,07 CNY
2025e	0,27 CNY	0 CNY	−0,21 CNY
2026e	0,46 CNY	0 CNY	0,05 CNY
2027e	0,63 CNY	0 CNY	−0,04 CNY

	Akcijų skaičius
2016	132,02 mln. Aktien
2017	160,00 mln. Aktien
2018	168,58 mln. Aktien
2019	866,73 mln. Aktien
2020	1,05 mlrd. Aktien
2021	1,17 mlrd. Aktien
2022	1,17 mlrd. Aktien
2023	1,26 mlrd. Aktien
2024	1,28 mlrd. Aktien
2025e	1,28 mlrd. Aktien
2026e	1,28 mlrd. Aktien
2027e	1,28 mlrd. Aktien

%	Pavadinimas	Akcijos	Pokytis	Data
22,98871 %	WuXi Healthcare Management, LLC	293 381 444	0	2023-12-31
11,17072 %	Boyu Capital Holdings Ltd	142 560 448	0	2023-12-31
9,08392 %	Pfizer Corporation Hong Kong Ltd.	115 928 803	0	2023-12-31
5,01727 %	Suzhou Oriza Holdings Co., Ltd.	64 030 316	−11 523 414	2024-09-17
1,27952 %	Yang (Jianxin)	16 329 256	25 000	2025-02-19
0,64349 %	Templeton Asset Management Ltd.	8 212 261	3 366 000	2024-09-30
0,31476 %	Invesco Hong Kong Limited	4 017 000	4 017 000	2024-12-31
0,20353 %	Hitchner III (Kenneth Walton)	2 597 485	15 995	2024-12-10
0,07217 %	Hu (Edward)	921 000	921 000	2024-10-25
0,06084 %	California Public Employees' Retirement System	776 500	20 500	2023-06-30
0,00913 %	State Street Global Advisors (US)	116 500	−4 000	2024-12-31
0,00835 %	Exchange Traded Concepts, LLC	106 500	0	2023-09-30
0,00564 %	China Asset Management (Hong Kong) Limited	72 000	0	2023-09-30
0 %	Xinyuan Asset Management Co., Ltd.	0	−745 000	2023-12-31
0 %	Ping An Fund Management Company Limited	0	−147 500	2024-06-30
0 %	China Universal Asset Management Co., Ltd.	0	−191 000	2023-06-30
0 %	GF Fund Management Co., Ltd.	0	−8 699 000	2024-06-30
0 %	E Fund Management Co. Ltd.	0	−88 000	2023-06-30
0 %	Yinhua Fund Management Co., Ltd.	0	−40 500	2023-06-30
0 %	Bosera Asset Management Co., Ltd.	0	−20 593 000	2024-06-30
0 %	China Asset Management Co., Ltd.	0	−787 000	2023-06-30
0 %	Vanguard Investments Australia Ltd.	0	−49 855	2024-12-31
0 %	Penghua Fund Management Co., Ltd.	0	−220 500	2023-06-30
0 %	Harvest Fund Management Co., Ltd.	0	−244 500	2024-06-30
0 %	Norges Bank Investment Management (NBIM)	0	−2 358 745	2023-12-31
0 %	BlackRock Investment Management (Australia) Ltd.	0	−25 500	2024-02-29
0 %	The Vanguard Group, Inc.	0	−2 893 915	2024-12-31
0 %	HSBC Global Asset Management (UK) Limited	0	−37 628	2023-11-30
0 %	BlackRock Advisors (UK) Limited	0	−353 624	2023-12-31
0 %	State Street Global Advisors Ireland Limited	0	−95 500	2023-12-31
0 %	BlackRock Institutional Trust Company, N.A.	0	−2 202 500	2023-12-31
0 %	Dimensional Fund Advisors, L.P.	0	−439 500	2024-07-31
0 %	Nuveen LLC	0	−516 500	2023-11-30
0 %	Vanguard Global Advisers LLC	0	−43 500	2024-09-30

Pavadinimas	Santykis	Dviejų savaičių koreliacija	Vieno mėnesio koreliacija	Trymėnesio koreliacija	Šešių mėnesių koreliacija	Vienmečio koreliacija
Agios Pharmaceuticals	TiekėjasKlientas	0,86	0,20	0,71	0,77	0,68
Genetron Holdings ADR	TiekėjasKlientas	0,75	0,11	0,77	0,82	0,71
WuXi AppTec Co H	TiekėjasKlientas	0,73	-0,16	0,13	0,60	0,72
Burning Rock Biotech ADR	TiekėjasKlientas	0,58	0,06	0,55	0,70	0,64
Amoy Diagnosti A Rg	TiekėjasKlientas	0,49	-0,28	0,54	0,85	0,70
Blueprint Medicines	TiekėjasKlientas	0,21	0,32	0,15	0,69	0,72
Wuxi Biologics	TiekėjasKlientas	0,11	0,22	0,16	0,82	0,80
Pfizer	TiekėjasKlientas	-0,01	0,36	-0,31	0,54	-0,45
Sinopharm Group H	TiekėjasKlientas	-0,29	0,01	0,12	-0,22	0,42
ABL Bio	TiekėjasKlientas	-0,29	0,21	0,79	0,28	-0,56

What values and corporate philosophy does CStone Pharmaceuticals represent?

CStone Pharmaceuticals represents a set of core values and a corporate philosophy that guides its operations and growth. Committed to advancing innovative therapies and transforming patients' lives, CStone Pharmaceuticals focuses on integrity, dedication, and excellence in all aspects of its business. By adhering to rigorous scientific standards and maintaining transparency, the company strives to deliver high-quality treatments and improve healthcare outcomes. CStone Pharmaceuticals prioritizes collaboration and partnerships to accelerate the development and commercialization of breakthrough therapies. With a strong emphasis on patient-centric approaches and a relentless pursuit of scientific innovation, CStone Pharmaceuticals aims to make a significant impact in the field of biopharmaceuticals.

In which countries and regions is CStone Pharmaceuticals primarily present?

CStone Pharmaceuticals is primarily present in China.

What significant milestones has the company CStone Pharmaceuticals achieved?

CStone Pharmaceuticals is a leading biopharmaceutical company that has achieved several significant milestones. The company successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange in 2019, raising substantial capital for its operations. CStone Pharmaceuticals also entered into strategic collaborations with global pharmaceutical companies like Pfizer and Bayer, enhancing its research and development capabilities. Furthermore, the company received approval for its first-in-class drug, CS1001, from the National Medical Products Administration in China, marking a major breakthrough in the field of immuno-oncology. With these accomplishments, CStone Pharmaceuticals has demonstrated its commitment to advancing innovative treatments for patients worldwide.

What is the history and background of the company CStone Pharmaceuticals?

CStone Pharmaceuticals is a leading biopharmaceutical company specializing in the development and commercialization of innovative immunotherapies and precision medicine to serve patients with cancer. Founded in 2015, CStone is headquartered in Suzhou, China, with global operations and collaborations to advance the treatment landscape for patients globally. The company focuses on developing first-in-class and best-in-class therapies that target multiple tumor types, including globally unmet medical needs. With a strong pipeline of potential drug candidates and a commitment to research and development, CStone Pharmaceuticals aims to make a meaningful impact on the lives of cancer patients worldwide.

Who are the main competitors of CStone Pharmaceuticals in the market?

The main competitors of CStone Pharmaceuticals in the market include companies such as BeiGene, Innovent Biologics, Jiangsu Hengrui Medicine, and Hutchison China MediTech.

In which industries is CStone Pharmaceuticals primarily active?

CStone Pharmaceuticals is primarily active in the biopharmaceutical industry.

What is the business model of CStone Pharmaceuticals?

CStone Pharmaceuticals follows a strategic business model focused on developing and commercializing innovative immunotherapies to address unmet medical needs. As a leading biopharmaceutical company in China, CStone concentrates on researching and producing novel, first-in-class oncology therapeutics. Leveraging collaborations, CStone invests in clinical development, regulatory filings, and commercialization activities, aiming to deliver transformative medicines to cancer patients. By combining internal R&D capabilities with partnerships, CStone targets various cancer indications, including lung, liver, colorectal, and gastric cancers, among others. With a commitment to improving patient outcomes, CStone Pharmaceuticals is dedicated to advancing the field of oncology through cutting-edge therapies.

Koks yra CStone Pharmaceuticals 2025 KGV?

P/E santykio šiuo metu CStone Pharmaceuticals apskaičiuoti negalima.

Koks CStone Pharmaceuticals 2025 KUV?

KUV šiuo metu negali būti apskaičiuotas CStone Pharmaceuticals.

Koks yra CStone Pharmaceuticals AlleAktien kokybės įvertinimas?

AlleAktien kokybės įvertis CStone Pharmaceuticals yra 2/10.

Koks yra CStone Pharmaceuticals 2025 pajamų dydis?

tikėtina CStone Pharmaceuticals pardavimai yra 342,56 mln. CNY.

Kokia yra CStone Pharmaceuticals 2025 pelnas?

tikėtina CStone Pharmaceuticals pelnas yra −273,36 mln. CNY.

Ką daro CStone Pharmaceuticals?

CStone Pharmaceuticals is a leading biotechnology company focused on the development and marketing of innovative cancer drugs. The company was founded in 2015 and is headquartered in Suzhou, China, operating globally. CStone Pharmaceuticals aims to develop new cancer drug candidates and market them in collaboration with established partners. The company works to address the need for drugs in oncology, immunology, autoimmunity, and connective tissue to maximize treatment options. The company has a broad pipeline, including various products such as CS1001, a PD-L1 antibody; CS1002, an anti-CD38 antibody used for the treatment of multiple myeloma and other malignant diseases; and CS3006, a tyrosine kinase inhibitor (TKI) that acts against cancer diseases like lung and breast cancer. CStone Pharmaceuticals has also agreed to collaborate with Pfizer to jointly develop CS1003, an anti-PD-1 antibody, and CS2006, an anti-CTLA4 antibody. This partnership aims to leverage the strengths of both companies and accelerate product development at a fast pace. The company maintains strong partnerships with various firms such as Blueprint Medicines, Agios Pharma, and others to promote innovative cancer drug candidates. Additionally, it collaborates closely with leading academic institutions and research facilities to develop new therapy options. CStone Pharmaceuticals also offers clinical trials to investigate the safety and efficacy of its drugs. The clinical studies aim to support FDA and European regulatory authorities in bringing the drugs to market. The company has ambitious plans to grow and achieve a leading position in cancer drug development and marketing in the future. CStone Pharmaceuticals is working to expand its product diversity and pipeline to meet the needs of patients. Simultaneously, the company will continue to expand partnerships with other companies and research institutions to develop innovative therapies and expand in the field of cancer drugs. Overall, CStone Pharmaceuticals' business model is focused on the development, marketing, and sale of innovative cancer drugs. The company relies on a broad pipeline and strong partnerships to achieve its vision and become one of the leading forces in the oncology industry, particularly in the Chinese market.

Kokia yra CStone Pharmaceuticals dividendė?

CStone Pharmaceuticals moka dividendą 0 CNY, kuris yra paskirstytas per išmokas per metus.

Kiek kartų CStone Pharmaceuticals moka dividendą?

Dividenda šiuo metu negali būti apskaičiuota CStone Pharmaceuticals arba įmonė dividendų nemoka.

Kas yra CStone Pharmaceuticals ISIN?

CStone Pharmaceuticals ISIN yra KYG2588M1006.

Kas yra CStone Pharmaceuticals WKN?

CStone Pharmaceuticals WKN yra A2PEFW.

Kas yra CStone Pharmaceuticals Tickeris?

CStone Pharmaceuticals akcijų simbolis yra 2616.HK.

Kiek dividendų moka CStone Pharmaceuticals?

Per paskutinius 12 mėnesių CStone Pharmaceuticals išmokėjo dividendą, kurios dydis siekė . Tai atitinka maždaug dividendų grąžą. Artimiausiems 12 mėnesiams CStone Pharmaceuticals tikėtina išmokės dividendus, kurie sudarys 0 CNY.

Kokia yra CStone Pharmaceuticals dividendų grąža?

CStone Pharmaceuticals šiuo metu yra dydžio dividendų grąža.

Kada CStone Pharmaceuticals moka dividendus?

CStone Pharmaceuticals moka dividendus kas ketvirtį. Jie išmokami mėnesiais.

Kokia saugi yra CStone Pharmaceuticals dividendų išmokėjimas?

CStone Pharmaceuticals per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Kokia yra CStone Pharmaceuticals dividendų suma?

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0 CNY. Tai atitinka 0 % dividendų grąžos procentą.

Kokiame sektoriuje yra CStone Pharmaceuticals?

CStone Pharmaceuticals priskiriamas sektoriui "Sveikata".

Wann musste ich die Aktien von CStone Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

Norėdamas gauti paskutinį CStone Pharmaceuticals dividendą nuo 2025-07-14, kurio dydis yra 0 CNY, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2025-07-14.

Kada CStone Pharmaceuticals paskutinį kartą mokėjo dividendą?

Paskutinės dividendų išmokėjimas įvyko 2025-07-14.

Kokia buvo CStone Pharmaceuticals dividendų suma 2024 metais?

2024 metais CStone Pharmaceuticals išmokėjo 0 CNY dividendų.

Kokia valiuta CStone Pharmaceuticals moka dividendus?

CStone Pharmaceuticals dividendai yra mokami CNY.

Birža	CStone Pharmaceuticals Akcijų kodas
DIUSELDORFAS	PH4.DU
FRANKFURTAS	PH4.F
HKSE	2616.HK
MIUNCHENAS	PH4.MU
PNK	CSPHF

CStone Pharmaceuticals Akcijų kodas	CStone Pharmaceuticals FIGI
2616:HK	BBG00N9XPM92
PH4:TH	BBG00PBHM8X6
PH4:GR	BBG00PG37985
PH4:GF	BBG00PG37994
PH4:GD	BBG00PG379B1
PH4:GS	BBG00PG379D9
PH4:GM	BBG00PG379F7
PH4:GB	BBG00PG379G6
2616EUR:XS	BBG00PGBZPR9
2616EUR:XH	BBG00PGBZPV4
2616EUR:XF	BBG00PGBZPX2
2616EUR:XE	BBG00PGBZPZ0
2616EUR:XJ	BBG00PGBZQ06
2616EUR:XL	BBG00PGBZQ15
2616EUR:XG	BBG00PGBZQ24
2616EUR:XO	BBG00PGBZQ33
2616EUR:XA	BBG00PGBZQ79
2616EUR:E1	BBG00PGBZQ88
2616EUR:XT	BBG00PGBZQ97
2616EUR:XW	BBG00PGBZQB4
2616EUR:XU	BBG00PGBZQC3
2616EUR:XV	BBG00PGBZQD2
2616EUR:XM	BBG00PGBZQF0
2616EUR:XQ	BBG00PGBZQG9
2616EUR:XX	BBG00PGBZQH8
2616EUR:XZ	BBG00PGBZQJ6
2616EUR:EU	BBG00PGBZQL3
PH4:QT	BBG00PGSC0Z3
2616EUR:EP	BBG00PGWYNR9
2616EUR:EZ	BBG00PGWYNT7
2616HKD:EP	BBG00RMFJNQ3
2616HKD:EZ	BBG00RMFJNT0
2616HKD:XS	BBG00RMFJNV7
2616HKD:X2	BBG00RMFJNW6
2616HKD:XH	BBG00RMFJNY4
2616HKD:XF	BBG00RMFJP06
2616HKD:XE	BBG00RMFJP24
2616HKD:XJ	BBG00RMFJP33
2616HKD:XL	BBG00RMFJP42
2616HKD:XG	BBG00RMFJP51
2616HKD:XO	BBG00RMFJP60
2616HKD:XA	BBG00RMFJPB4
2616HKD:E1	BBG00RMFJPC3
2616HKD:XT	BBG00RMFJPD2
2616HKD:XW	BBG00RMFJPF0
2616HKD:XU	BBG00RMFJPG9
2616HKD:XV	BBG00RMFJPJ6
2616HKD:XM	BBG00RMFJPK4
2616HKD:XQ	BBG00RMFJPL3
2616HKD:XX	BBG00RMFJPM2
2616HKD:XZ	BBG00RMFJPN1
2616HKD:X1	BBG00RMFJPQ8
2616HKD:EU	BBG00RMFJPS6
CSPHF:US	BBG00RP1HQC1
CSPHF:PQ	BBG00RP1HQS4
CSPHF:UV	BBG00RP1HQT3
PH4:GZ	BBG00Z47QSQ4
2616:H2	BBG012DZLHM7
PH4:LA	BBG018H9RQW1
PH4:LU	BBG018J3F8N5
2616:H1	BBG01FRSR9D1

Professional-grade financial intelligence

Kursas

Akcijos kaina

Akcijų kodas2616.HK

ISINKYG2588M1006

VVPA2PEFW

CStone Pharmaceuticals akcijų kaina

Kursas

Apžvalga

Intraday funkcija

Bendroji grąža ir santykinė kainų pokyčiai

Interpretacija ir investavimas

CStone Pharmaceuticals Akcijų istorija

CStone Pharmaceuticals akcijų apyvarta, EBIT, pelnas KYG2588M1006 · A2PEFW

Pajamos, pelnas & EBIT

Supratimas apie pajamas, EBIT ir pelną

Metinė analizė ir palyginimai

Išnaudoti lūkesčius investuojant

Investicijų įžvalgos

CStone Pharmaceuticals Pajamų, pelno ir EBIT istorija.

CStone Pharmaceuticals Akcijų rodikliai

GuV

Pajamos ir augimas

Bruto marža

EBIT ir EBIT marža

Pajamos ir jų augimas

Leidžiamų akcijų skaičius

Metinių duomenų palyginimo interpretacija

Lūkesčiai ir prognozės

Balansas

Balanso supratimas

Turtas

Įsipareigojimai

Nuosavas kapitalas

Metų po metų analizė

Duomenų interpretacija

CStone Pharmaceuticals Akcijos Maržos KYG2588M1006 · A2PEFW

Margen

Supratimas apie bruto maržą

EBIT maržos analizė

Pardavimų maržos įžvalgos

Lūkesčių interpretavimas

Lyginamoji analizė

CStone Pharmaceuticals Maržų istorija

CStone Pharmaceuticals akcijos apyvarta, EBIT, pelnas vienai akcijai KYG2588M1006 · A2PEFW

Pardavimai, EBIT ir Pelnas vienai akcijai

Pajamos vienai akcijai

EBIT vienai akcijai

Pelnas vienai akcijai

Tikėtinos vertės

CStone Pharmaceuticals Pardavimų, pelno ir EBIT istorija vienai akcijai

CStone Pharmaceuticals akcija ir akcijų analizė

Padaryk geriausias savo gyvenimo investicijas

CStone Pharmaceuticals vertinimas pagal Fair Value

Fair Value

Supratimas apie Fair Value

Pajamų pagrindu skaičiuojamas Fair Value

Apyvartos pagrindu skaičiuojamas Fair Value

Dividendų pagrindu skaičiuojamas Fair Value

Lūkesčiai ir prognozės

Palyginamoji analizė

CStone Pharmaceuticals įvertinimas pagal istorinį P/E, EBIT ir P/S

Padaryk geriausias savo gyvenimo investicijas

CStone Pharmaceuticals akcijų skaičius KYG2588M1006 · A2PEFW

Pardavimai, EBIT ir Pelnas vienai akcijai

Pajamos vienai akcijai

EBIT vienai akcijai

Pelnas vienai akcijai

Tikėtinos vertės

Padaryk geriausias savo gyvenimo investicijas

CStone Pharmaceuticals Pelno prognozės

CStone Pharmaceuticals Pelnų staigmenos

CStone Pharmaceuticals akcijos akcininkų struktūra

CStone Pharmaceuticals Valdyba ir Priežiūros taryba

Mr. Ting Yuk Wu

Mr. Kenneth Hitchner

Dr. Paul Chew

Mr. Hongbin Sun

Dr. Wei Li

Dr. Jianxin Yang

Akcijų kodas
2616.HK

ISIN
KYG2588M1006

VVP
A2PEFW